Results 1 to 10 of about 4,156,285 (177)

Effect of PIVKA‐II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery [PDF]

open access: yesCancer Medicine, 2023
Background Prothrombin induced by vitamin K absence‐II (PIVKA‐II) and Alpha‐fetoprotein (AFP) have been widely used as diagnostic markers in hepatocellular carcinoma (HCC), but the prognostic values of the two serum markers and their clinical usefulness ...
Yunshi Cai, Kunlin Xie, Haifeng Wan
exaly   +4 more sources

PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.

open access: yesPLoS ONE, 2021
BackgroundPancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC ...
Sara Tartaglione   +5 more
doaj   +5 more sources

Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients [PDF]

open access: yesFrontiers in Public Health, 2022
Increased protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels had been widely reported in patients with hepatocellular carcinoma (HCC) and chronic hepatitis. However, the role of PIVKA-II in hepatitis E is unclear.
Shanshan Li, Hui Shao, Naibin Yang
exaly   +5 more sources

Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II

open access: yesClinical Biochemistry, 2015
Protein induced by vitamin K absence or antagonist-II (PIVKA-II) has been used as a tumor marker to aid in the diagnosis of hepatocellular carcinoma (HCC). We developed an anti-PIVKA-II monoclonal antibody, 3C10, and a fully automated quantitative immunoassay for PIVKA-II on the ARCHITECT® i-systems.
Toru Yoshimura
exaly   +4 more sources

Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma [PDF]

open access: yesScientific Reports, 2023
The high morbidity and mortality of hepatocellular carcinoma (HCC) has encouraged the search for new biomarkers to be used alongside alpha-foetoprotein (AFP) and imaging tests.
Francisco Villalba-López   +9 more
doaj   +2 more sources

Effect of AFP and PIVKA-II secretion status on prognosis of advanced hepatocellular carcinoma patients receiving TACE combined with systemic therapy [PDF]

open access: yesBMC Cancer
Background Few biomarkers can predict the effectiveness of transcatheter arterial chemoembolization (TACE) in combination with systemic therapies for patients with advanced hepatocellular carcinoma (HCC).
Jinfeng Bai   +6 more
doaj   +2 more sources

Pilot Study of PIVKA-II in the Prognostic Assessment of Hepatocellular Carcinoma in Chronic Viral Hepatitis: Comparative Findings from HBV and HCV Cohorts from a Single Center in Serbia [PDF]

open access: yesBiomedicines
Background: Hepatocellular carcinoma (HCC) frequently develops in patients with chronic hepatitis B and C. Early detection is critical, but current methods, including ultrasound and AFP, have suboptimal accuracy.
Ivana Milošević   +7 more
doaj   +2 more sources

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma

open access: yesJournal of Interventional Medicine, 2021
Objective: To explore the diagnostic value of abnormal prothrombin Ⅱ (PIVKA-Ⅱ) and alpha-fetoprotein (AFP) in primary hepatocellular carcinoma (HCC). Methods: From 2018 0.01 to 2020.01, there were 158 patients with primary liver cancer caused by chronic ...
Qiuyan Lee, Xixiang Yu, Weiwei Yu
exaly   +3 more sources

Diagnostic and prognostic performance of serum GPC3 and PIVKA-II in AFP-negative hepatocellular carcinoma and establishment of nomogram prediction models [PDF]

open access: yesBMC Cancer
Objective A significant proportion, ranging from 20 to 40%, of individuals with hepatocellular carcinoma (HCC) do not exhibit elevated Alpha-fetoprotein (AFP) levels. This study aimed to evaluate the utility of serum glypican-3 (GPC3) and protein induced
Yingying Lin   +6 more
doaj   +2 more sources

PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma [PDF]

open access: yesBMC Cancer
Background Alpha-fetoprotein (AFP) is a key biomarker for hepatocellular carcinoma (HCC), but 30–40% of cases are AFP-negative. Prothrombin induced by vitamin K absence II (PIVKA-II) is more sensitive for HCC detection, though its role in systemic ...
San-Chi Chen   +7 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy